Subchronic administration of phenobarbital alters the mutation spectrum of lacI in the livers of Big Blue® transgenic mice

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 448, Issue 1, 2000, Pages 69-80

  Shane, B S ^a   Smith Dunn, D L ^a   Deboer, J G ^b   Glickman, B W ^b   Cunningham, M L ^c  

^a LOUISIANA STATE UNIVERSITY   (United States)

^b UNIVERSITY OF VICTORIA   (Canada)

^c NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

Author keywords

Big Blue mice; In vivo mutations; Mutation spectrum; Oxazepam; Phenobarbital

Indexed keywords

CYTOCHROME P450 ISOENZYME; OXAZEPAM; PHENOBARBITAL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BASE PAIRING; CONTROLLED STUDY; DNA ADDUCT; DNA DAMAGE; ENZYME INDUCTION; GENE FREQUENCY; GENE MUTATION; LIVER; MALE; MOUSE; MUTAGENICITY; NONHUMAN; PRIORITY JOURNAL; TRANSGENIC MOUSE;

ANIMALS; BACTERIAL PROTEINS; DRUG ADMINISTRATION SCHEDULE; ESCHERICHIA COLI PROTEINS; HYPNOTICS AND SEDATIVES; LIVER; MALE; MICE; MICE, TRANSGENIC; MITOGENS; MUTAGENICITY TESTS; MUTATION; PHENOBARBITAL; REPRESSOR PROTEINS;

ANIMALIA; MUS MUSCULUS;

EID: 0034646274     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0027-5107(00)00002-6     Document Type: Article

References (61)

1. Whysner J., Ross P.M., Williams G.M. Phenobarbital mechanistic data and risk assessment: enzyme induction, enhanced cell proliferation, and tumor promotion. Pharmacol. Ther. 71:1996;153-191.
2. Albertini S., Gocke E. Phenobarbital: does the positive result in TA1535 indicate genotoxic properties? Environ. Mol. Mutagen. 19:1992;161-166.
3. Zeiger E., Haworth S. Tests with a preincubation modification of the Salmonella/microsome assay. Prog. Mutat. Res. 5:1985;187-199.
4. McCann J., Choi E., Yamasaki E., Ames B.N. Detection of carcinogens as mutagens in the Salmonella/microsome test: assay of 300 chemicals. Proc. Natl. Acad. Sci. U.S.A. 72:1975;5135-5139.
5. Matsushima T., Muramatsu M., Haresaku M. Mutation tests on Salmonella typhimurium by the preincubation method. Prog. Mutat. Res. 5:1985;181-186.
6. +/- assay system. Prog. Mutat. Res. 5:1985;487-496.
7. Myhr B., Bowers L., Caspary W.J. Assays for the induction of gene mutations at the thymidine kinase locus in L5178Y mouse lymphoma cells in culture. Prog. Mutat. Res. 5:1985;555-568.
8. Preston R.J., Dean B.J. Tests for the induction of chromosome aberrations, polyploidy and sister-chromatid exchanges in rat liver (RL4) cells. Prog. Mutat. Res. 5:1985;387-395.
9. Gulati D.K., Sabharwal P.N., Shelby M.D. Tests for the induction of chromosomal aberrations and sister chromatid exchanges in cultured Chinese hamster (CHO) ovary cells. Prog. Mutat. Res. 5:1985;413-426.
10. Monographs on the Evaluation of Carcinogenic Risks to Humans. Overall Evaluations of Carcinogenicity: An Updating of IARC Monographs. Vols. 1-42:1987;IARC, Lyon, France. Suppl. 7.
11. Becker F.F. Morphological classification of mouse liver tumors based on biological characteristics. Cancer Res. 42:1982;3918-3923.
12. Cunninghame M.E., Evans J.G., Butler W.H. An ultrastructural study of spontaneous and phenobarbitone induced nodules in the mouse liver. Int. J. Exp. Pathol. 72:1991;695-703.
13. Evans J.G., Collins M.A., Lake B.G., Butler W.H. The histology and development of hepatic nodules and carcinoma in C3H/He and C57B1/6 mice following chronic phenobarbitone administration. Toxicol. Pathol. 20:1992;585-594.
14. Olsen J.H., Wallin H., Boice J.D., Rask K., Schulgren G., Fraumeni J.F. Phenobarbital, drug metabolism and human cancer. Cancer Epidemiol. Prev. 2:1993;449-452.
15. Randerath K., van Golen K.L., Dragan Y.P., Pitot H.C. Effects of phenobarbital on I-compounds in liver DNA as a function of age in male rats fed two different diets. Carcinogenesis. 13:1992;125-130.
16. 32P-postlabeling assay. Toxicol. Appl. Pharmacol. 148:1998;14-23.
17. Halliwell B., Aruoma O. DNA damage by oxygen-derived species. FEBS Lett. 281:1991;9-19.
18. Klaunig J.E., Xu Y., Isenberg J.S., Bachowski S., Kolaja K.L., Jiang J., Stevenson D.E., Walborg E.F. Jr. The role of oxidative stress in chemical carcinogenesis. Environ. Health Perspect. 106(Suppl. 1):1998;235-240.
19. Smith P.F., O'Brien K.A., Keenan K.P. Evaluation of bromodeoxyuridine labeling in hepatomegaly produced by peroxisomal proliferation of P450 induction in rodents. Prog. Clin. Biol. Res. 368:1991;285-289.
20. Counts J.L., Sarmiento J.I., Harbison M.L., Downing J.C., McClain M., Goodman J.I. Cell proliferation and global methylation status changes in mouse liver after phenobarbital and/or choline-devoid, methionine-deficient diet administration. Carcinogenesis. 17:1996;1251-1257.
21. Zhang Y., Chiao C., Byrd L.L., Kaufman D.G., Kaufman W.K. Liver tumor promotion and the suppression of p-53 dependent cell cycle checkpoint function. Jirtle R.L. Liver Regeneration and Carcinogenesis. 1995;179-197 Academic Press, New York, USA.
22. Schulte-Hermann R., Grasl-Kraupp B., Bursch W. Apoptosis and hepatocarcinogenesis. Jirtle R.L. Liver Regeneration and Carcinogenesis. 1995;141-178 Academic Press, New York, USA.
23. Guppy M.J., Wilton J.C., Sharma R., Coleman R., Chipman J.K. Modulation of phenobarbitone-induced loss of gap junctional intercellular communication in hepatocyte couplets. Carcinogenesis. 15:1994;1917-1921.
24. Kohler S.W., Provost G.S., Fieck A., Kretz P.L., Bullock W.O., Putman D.L., Sorge J.A., Short J.M. Analysis of spontaneous and induced mutations in transgenic mice using a lambda ZAP/lacI shuttle vector. Environ. Mol. Mutagen. 18:1991;316-321.
25. Mirsalis J.C., Monforte J.A., Winegar R.A. Transgenic animal models for measuring mutations in vivo. Crit. Rev. Toxicol. 24:1994;255-280.
26. Hayward J.J., Shane B.S., Tindall K.R., Cunningham M.L. Analysis of in vivo mutation frequency in liver DNA of lacI transgenic mice following subchronic exposure to the carcinogen-noncarcinogen pair 2,4- and 2,6-diaminotoluene. Carcinogenesis. 16:1995;2429-2433.
27. Shane B.S., deBoer J.G., Glickman B.W., Cunningham M.L. The benzodiazepine, oxazepam, is genotoxic in vivo in Big Blue® mice. Carcinogenesis. 20:1999;1315-1321.
28. Erfle H., Walsh D., Holcroft J., Hague N., deBoer J.G., Glickman B.W. An efficient laboratory protocol for the sequencing of large numbers of lacI mutants recovered from Big Blue® transgenic animals. Environ. Mol. Mutagen. 28:1996;393-396.
29. Adams W.T., Skopek T.R. Statistical test for the comparison of samples from mutational spectra. J. Mol. Biol. 194:1987;391-396.
30. Cunningham M.L. Role of increased DNA replication in the carcinogenic risk of nonmutagenic chemical carcinogens. Mutat. Res. 365:1996;59-69.
31. deBoer J.G., Erfle H., Walsh D., Holcroft J., Provost J.S., Rogers B., Tindall K.R., Glickman B.W. Spectrum of spontaneous mutations in liver tissue of lacI transgenic mice. Environ. Mol. Mutagen. 30:1997;273-286.
32. Gajewski E., Rao G., Nackerdien Z., Dizdaroglu M. Modification of DNA bases in mammalian chromatin by radiation-generated free radicals. Biochemistry. 29:1990;7876-7882.
33. Shigenaga M.K., Gimeno C.J., Ames B.N. Urinary 8-hydroxy-2′-deoxyguanosine as a biological marker of in vivo DNA damage. Proc. Natl. Acad. Sci. U.S.A. 86:1989;9697-9701.
34. 15N Nuclear magnetic resonance studies on the tautomerism of 8-hydroxy-2′-deoxyguanosine, 8-hydroxyguanosine and other C8-substituted guanine residues. Chem. Res. Toxicol. 3:1990;445-452.
35. Michaels M.L., Cruz C., Grollman A.P., Miller J.H. Evidence that MutY and MutM combine to prevent mutations by an oxidatively damaged form of guanine in DNA. Proc. Natl. Acad. Sci. U.S.A. 89:1992;7022-7025.
36. Sakumi K., Furuichi M., Tsuzuki T., Kakuma T., Kawabata S., Maki H., Sekiguchi M. Cloning and expression of cDNA for a human enzyme that hydrolyzes 8-oxo-dGTP, a mutagenic substrate for DNA synthesis. J. Biol. Chem. 268:1993;23524-23530.
37. Wood M.L., Esteve A., Morningstar M.L., Kuziemko G.M., Essigman J.M. Genetic effects of oxidative DNA damage: comparative mutagenesis of 7,8-dihydro-8-oxo-guanine and 7,8-dihydro-8-oxoadenine in Escherichia coli. Nucleic Acids Res. 22:1992;6023-6032.
38. Retel J., Hoebee B., Braun J.E.F., Lutgerink J.T., van der Akker E., Wanamarta A.H., Joenje H., LaFleur M.V.M. Mutational specificity of oxidative DNA damage. Mutat. Res. 299:1993;165-182.
39. McBride T.J., Preston B.D., Loeb L.A. Mutagenic spectrum resulting from DNA damage by oxygen radicals. Biochemistry. 30:1991;207-213.
40. Wang D., Kreutzer D.A., Essigmann J.M. Mutagenicity and repair of DNA damage: insights from studies using defined lesions. Mutat. Res. 400:1998;99-115.
41. Kamiya H., Murata-Kamiya N., Koizume S., Inoue H., Nishimura S., Ohtsuka E. 8-Hydroxyguanine (7,8-dihydro-8-oxoguanine) in hot spots of the c-Ha-ras gene: effects of sequence contexts on mutation spectra. Carcinogenesis. 16:1995;883-889.
42. Singh V.K., Ganesh L., Cunningham M.L., Shane B.S. Can the mutagenicity of weak or non-mutagenic carcinogens be detected at the cII locus in Big Blue® transgenic mice. Environ. Mol. Mutagen. 33(Suppl. 30):1999;58.
43. Gunz D., Shephard S.E., Lutz W.K. Can nongenotoxic carcinogens be detected with the lacI transgenic mouse mutation assay? Environ. Mol. Mutagen. 21:1993;209-211.
44. Okey A.B. Enzyme induction in the cytochrome P450 system. Pharmacol. Ther. 45:1990;241-298.
45. Collins M.A., Lake B.G., Evans J.G., Walker R., Gangolli S.D., Conning D.M. Sustained induction of hepatic xenobiotic metabolizing enzyme activities by phenobarbitone in C3H/He mice: relevance to nodule formation. Toxicology. 33:1984;129-144.
46. Waxman D.J., Azaroff L. Phenobarbital induction of cytochrome P450 gene expression. Biochem. J. 281:1992;577-592.
47. Ekstrom G., Ingleman-Sundberg M. Rat liver microsomal NADPH-supported oxidase activity and lipid peroxidation dependent on ethanol-inducible cytochrome P450 (P450IIE1). Biochem. Pharmacol. 38:1989;1313-1319.
48. Floyd R.A. The role of 8-hydroxyguanine in carcinogenesis. Carcinogenesis. 11:1990;1447-1450.
49. Paolini M., Pozzetti L., Pedulli G.F., Cipollone M., Mesirca R., Forti G.C. Paramagnetic resonance in detecting carcinogenic risk from cytochrome P450 overexpression. J. Invest. Med. 44:1996;470-473.
50. Vaca C.E., Wilhelm J., Harms-Ringdahl M. Studies on lipid peroxidation in rat liver nuclei and isolated nuclear membranes. Biochim. Biophys. Acta. 958:1988;375-387.
51. Pryor W.A., Porter N.A. Suggested mechanisms for the production of 4-hydroxynonenal from the auto-oxidation of polyunsaturated fatty acids. Free Radicals Biol. Med. 8:1990;541-543.
52. 4-ethenocytosine by lipid peroxidation products and nucleic acid bases. Chem. Res. Toxicol. 8:1995;278-283.
53. 4O-methyldeoxythymidine, using polymerases of varying fidelity. Carcinogenesis. 5:1984;1165-1171.
54. Cohen S.M., Ellwein L.B. Cell proliferation and carcinogenesis. Science. 249:1990;1007-1011.
55. Cohen S.M., Ellwein L.B. Genetic errors, cell proliferation and carcinogenesis. Cancer Res. 51:1991;6493-6505.
56. Wolff G.L., Morrissey R.L., Chen J.J. Susceptible and resistant subgroups in genetically identical populations: response of mouse liver neoplasia and body weight to phenobarbital. Carcinogenesis. 7:1986;1935-1937.
57. B.S. Shane, J.G. deBoer, D.E. Watson, J.K. Haseman, B.W. Glickman, K.R. Tindall, lacI mutation spectra following benzo[a]pyrene treatment of Big Blue® mice, Carcinogenesis, accepted.
58. Griffin R.J., Dudley C.N., Cunningham M.L. Biochemical effects of the mouse hepatocarcinogen oxazepam: similarities to phenobarbital. Fundam. Appl. Toxicol. 29:1996;147-154.
59. Cunningham M.L., Maronpot R.R., Thompson M., Bucher J.R. Early responses of the liver of B6C3F1 mice to the hepatocarcinogen, oxazepam. Toxicol. Appl. Pharmacol. 124:1994;31-38.
60. Mills J.J., Jirtle R.L., Boyer I.J. Mechanism of liver tumor promotion. Jirtle R.L. Liver Regeneration and Carcinogenesis. 1995;199-226 Academic Press, New York, USA.
61. Lee G.-H., Ooasa T., Osanai M. Mechanism of the paradoxical, inhibitory effect of phenobarbital on hepatocarcinogenesis initiated in infant B6C3F1 mice with diethylnitrosamine. Cancer Res. 58:1998;1665-1669.